.jpg)
In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on PLx Pharma (PLXP – Research Report), with a price target of $21.00. The company’s shares closed last Friday at $12.31.
According to TipRanks.com, Butler is a 3-star analyst with an average return of 4.1% and a 42.8% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Aquestive Therapeutics, and ACADIA Pharmaceuticals.
PLx Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on PLx Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $16.5 million. In comparison, last year the company earned revenue of $27.91K and had a GAAP net loss of $5.6 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development of clinically validated and patent-protected PLxGuard delivery system. Its products include Vazalore 325 mg and PL1200 Ibuprofen 200 mg. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Houston, TX.
Read More on PLXP: